PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure
    PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure
    PRISM MarketView

    PRISM NextGen Tech Stocks Soundhound AI (SOUN) and Recursion Pharmaceuticals (RXRX) See Share Prices Soar From Nvidia Disclosure

    15 February 2024

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Today the megacap AI chipmaker Nvidia (NVDA) disclosed its stake in some smaller AI firms that has boosted shares for those associated with the disclosure.
    PRISM NextGen Tech stock Soundhound AI, Inc. (SOUN) rose by 73% upon Nvidia announcing its $3.7M investment in the conversational voice assistant developer while TechBio company Recursion Pharmaceuticals, Inc. (RXRX) is up 15% from Nvidia’s $76M investment.

    NextGen Stock Prices at Prism MarketView

    Technology continues to evolve as Artificial Intelligence becomes more prominent. The “next-gen wave” has contributed to additional technological advances s

    Read More

    SoundHound AI, Inc. - Prism MarketView

    SoundHound AI, Inc. - Prism MarketView

    SoundHound’s independent voice AI platform connects people to brands through customized conversational experiences that voice-enable products, services, and a

    Read More

    Recursion Pharmaceuticals, Inc. - Prism MarketView

    Recursion Pharmaceuticals, Inc. - Prism MarketView

    Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the

    Read More

    Other names who also saw positive share movements that were included in the disclosure were med device company Nano-X (NNOX), autonomous driving tech company TuSimple Holdings (TSPH), and chip designer, Arm Holdings (ARM).
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    PRISM MediaWire - Blogs
    To see this content properly accept cookies.
    PRISM MediaWire - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM MarketView
    Greenwich LifeSciences Provides Update on Phase III Clinical Trial for Breast Cancer Immunotherapy; Shares Surge

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, provided an update on its Phase III clinical trial, Flamingo-01, focusing on GLSI-100, an immunotherapy aimed at pr...

    15 February 2024

    PRISM MarketView
    Clever Leaves Gains Exclusive License to Cultivate High Performance Cannabis

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - As part of its partnership with award-winning Dutch seed bank, Paradise Seeds, global medicinal cannabis company, Clever Leaves Holdings (Nasdaq: CLVR), will develop and register high performance cannabis...

    15 February 2024

    PRISM MarketView
    Atara Biotherapeutics Files IND to Advance Lupus Treatment

    New York, February 15, 2024 - PRISM MarketView - PRISM MediaWire - Atara Biotherapeutics (Nasdaq: ATRA) has submitted an Investigational New Drug (IND) application to the FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus(SLE) w...

    15 February 2024

    PRISM MarketView
    PRISM MedDevice Mover: Sensus HealthCare

    New York, February 16, 2024 - PRISM MarketView - PRISM MediaWire - Sensus Healthcare, Inc. (Nasdaq: SRTS) is at the forefront of superficial radiation therapy devices, with a diverse product range aimed at treating non-melanoma skin cancers and various other cancers. The...

    16 February 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.